neurodegenerative brain diseases
Scope
Date
~
-
Bio & Pharma
HLB starts Phase 3 clinical trials for ophthalmic disease treatment in US
South Korea's pharmaceutical company HLB Therapeutics Co. announced on Thursday that it has started patient administration of "RGN-259," a treatment...
Apr 13, 2023 (Gmt+09:00)
-
Artificial intelligence
Kakao will launch Korean-specific vertical AI in year's first half
Kakao Corp., South Korea’s platform giant operating the country’s No. 1 chat app KakaoTalk, by the first half of the year will launch an...
Mar 29, 2023 (Gmt+09:00)
-
Artificial intelligence
Kakao Brain launches web service to turn imagination into images
Kakao Brain, a South Korean artificial intelligence (AI) company owned by Kakao Corp., launched an open beta version of "B^ EDIT," a web service tha...
Mar 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis launches ARMD biosimilar drug in Germany, Canada
Samsung Bioepis Co., a South Korean biosimilar firm, announced on Sunday that it has recently launched a new biosimilar drug called SB11 for the tre...
Mar 06, 2023 (Gmt+09:00)
-
Bio & Pharma
GC Biopharma introduces candidates for treating blood coagulation disease
South Korea's GC Biopharma Corp. announced on Tuesday that it had entered into an agreement to transfer assets with Catalyst Biosciences, a US-based...
Mar 02, 2023 (Gmt+09:00)
-
Artificial intelligence
Kakao Brain to launch investment fund for AI startups
Kakao Brain, a South Korean artificial intelligence (AI) company owned by Kakao Corp., said on Sunday it plans to set up a fund of up to 10 billion ...
Feb 27, 2023 (Gmt+09:00)
-
Healthcare
Daesang Wellife signs contract with RexSoft for healthcare platform
South Korea's Daesang Wellife Corp. has inked a 2 billion won ($1.5 million) investment contract with local healthcare data science company RexSoft ...
Feb 15, 2023 (Gmt+09:00)
-
Artificial intelligence
Kakao Brain presents text-based AI motion generation model
On Tuesday, Kakao Brain, the AI unit of South Korea's Kakao Corp., announced the development of a new text-based motion generation model, called "FL...
Feb 15, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N's GERD drug K-CAB gets approval in Mexico
South Korea's biohealth company HK inno.N said on Tuesday that its gastroesophageal reflux disease (GERD) treatment K-CAB (active ingredient: tegopr...
Feb 14, 2023 (Gmt+09:00)
-
Bio & Pharma
Hanall Biopharma invests in Interon Labs for brain disease treatments
South Korean pharmaceuticals firm Hanall Biopharma Co. is investing in Interon Laboratories, a US biotech firm that finds and develops treatments fo...
Feb 13, 2023 (Gmt+09:00)
-
Bio & Pharma
Humasis participates Dubai MEDLAB Middle East 2023
South Korean medical devices maker, Humasis Co., is participating in the MEDLAB Middle East 2023 event taking place at the Dubai World Trade Center ...
Feb 08, 2023 (Gmt+09:00)
-
Bio & Pharma
HK inno.N to introduce biosimilars for bone disease treatment from Spain
South Korea's biohealth company HK inno.N said on Wednesday that it has signed an agreement with Spanish pharmaceutical company mAbxience SA to intr...
Jan 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for EMA approval of smaller dose formulation of Yuflyma
Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...
Jan 16, 2023 (Gmt+09:00)
-
Bio & Pharma
S.Biomedics gets approval for Parkinson's disease clinical trials
South Korea's biomedicine firm S.Biomedics said on Friday that it has won approval from the Ministry of Food and Drug Safety for phase 1 and 2a clin...
Jan 13, 2023 (Gmt+09:00)
-
Bio & Pharma
HLB confirms ophthalmic disease treatment in phase 3 clinical trials
South Korea’s biomedicine startup HLB Therapeutics Co. said on Monday that its Neurotrophic Keratopathy (NK) treatment RGN-259 proved effectiv...
Jan 03, 2023 (Gmt+09:00)
-
Bio & Pharma
SK Chemicals introduces Tiglutik, treatment for Lou Gehrig's disease
SK Chemicals said on Monday that it is strengthening its portfolio of neurological diseases by introducing Tiglutik (riluzole), Lou Gehrig's disease...
Jan 02, 2023 (Gmt+09:00)
-
Bio & Pharma
CENYX Biotech, developing treatment for brain damage with ROS-scavenging, nano-sized heavy metals
When severe brain diseases such as cerebral infarction or cerebral hemorrhage occur, the blood-brain barrier (BBB) in our body no longer functions p...
Dec 26, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for FDA approval for Remsima SC
Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...
Dec 23, 2022 (Gmt+09:00)
-
Bio & Pharma
Bigsome Bio signs tech transfer agreement with university
Bigsome Bio, a subsidiary of Lotte Chilsung Beverage, has begun research on functional materials for respiratory health.The company said on Friday t...
Dec 20, 2022 (Gmt+09:00)
-
Bio & Pharma
S. Korea's GI Cell, Japanese partner to study cell therapy for blood cancer
South Korea's GI Cell, the cell therapy affiliate of GI Innovation, on Tuesday said it signed an agreement with Optieum Biotechnologies of Japan on ...
Dec 14, 2022 (Gmt+09:00)
-
Bio & Pharma
S.Korean biotech firm Noul signs MOU with disease center of Ghana
South Korea's Medical diagnostics company Noul Co., Ltd. said on Monday that it has signed a memorandum of understanding with the Ghana Infectious D...
Dec 12, 2022 (Gmt+09:00)
-
Artificial intelligence
Kakao Brain to unveil AI chest X-ray diagnosis service next year
Come next year, Kakao Brain, the artificial intelligence arm Kakao Corp., is slated to unveil an AI system that can write the first draft diagnosis ...
Dec 06, 2022 (Gmt+09:00)
-
Bio & Pharma
CJ partners with Emmyon to develop ingredients preventing muscle atrophy
South Korean food giant CJ CheilJedang Corp. announced on Tuesday that it has signed a license contract with Emmyon, an American biotechnology start...
Dec 06, 2022 (Gmt+09:00)
-
Bio & Pharma
Orion to enter dental disease treatment sector
Orion Corp., the Korean company, best known for its signature product choco pie, is entering drug development. Instead of indirectly running a joint...
Nov 30, 2022 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins trial against Regeneron for US patent lawsuit over biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced Friday that it won its first trial against New York-based biotech giant Regeneron Ph...
Nov 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis sees greater market for Byooviz eye disease biosimilar
NEW YORK – Samsung Bioepis Co., a biopharmaceutical unit of South Korea’s top conglomerate Samsung, is one step ahead of its rivals in t...
Jul 18, 2022 (Gmt+09:00)
-
Bio & Pharma
Pharma companies jump into $3 bn pet care market
South Korean pharmaceutical companies are jumping into the animal medicine and diagnostics market to target the rapidly growing pet care market, whi...
Jun 24, 2022 (Gmt+09:00)
-
Bio & Pharma
Samsung Bioepis’ SB12 shows same clinical effects as Alexion’s Soliris
Samsung Bioepis Co., a biopharmaceutical unit of Samsung Group, said its SB12, a proposed biosimilar to Alexion Pharmaceuticals Inc.’s rare bl...
Jun 14, 2022 (Gmt+09:00)
language -
Artificial intelligence
KAIST develops brain-like, large-scale memory system
The Korea Advanced Institute of Science & Technology (KAIST), a prestigious South Korean university, has developed a highly-reliable, large-scal...
Jun 08, 2022 (Gmt+09:00)
language -
Robotics
Koh Young’s medical robot conducts 100 brain surgeries a year
Koh Young Technology Inc., a South Korean 3D imagery tech company listed on the Kosdaq, announced on Tuesday that its medical robot Kymero has condu...
Jan 26, 2022 (Gmt+09:00)
Latest News
- 1 Seoul appeal: Korean art captivates Indonesia’s affluent connoisseurs
- 2 CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
- 3 Trump Jr. meets Korean business chiefs in back-to-back sessions
- 4 Samsung in talks to supply customized HBM4 to Nvidia, Broadcom, Google
- 5 Kookmin Bank raises $700 mn in forex bonds amid strong demand